{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T18:10:09Z","timestamp":1774203009487,"version":"3.50.1"},"reference-count":61,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"crossref","award":["SHDC2020CR3002A"],"award-info":[{"award-number":["SHDC2020CR3002A"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"crossref","award":["SHDC12018112"],"award-info":[{"award-number":["SHDC12018112"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Public Clincial Center","award":["KY-GW-2021-02"],"award-info":[{"award-number":["KY-GW-2021-02"]}]},{"name":"National Science Fundation of Xiamen","award":["3502Z20224012"],"award-info":[{"award-number":["3502Z20224012"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>A phase I clinical trial was conducted to assess the safety and feasibility of invariant natural killer T (iNKT) cells combined with PD-1+CD8+ T cells in patients with advanced pancreatic cancer and failing the first-line chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Fifteen eligible patients were enrolled, of whom 9 received at least three cycles of treatment each. In total, 59 courses were administered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fever was the most common adverse event, peaking at about 2\u20134 hours after cell infusion and reverting within 24 hours without treatment in all patients. Influenza-like reactions such as headache, myalgia, and arthralgia were also observed in 4, 4, and 3 of the patients, respectively. In addition, vomiting and dizziness were prevalent, while abdominal pain, chest pain, rash, and stuffy nose were rare adverse events, each reported in 1 patient. Side effects above grade 2 were not observed. Two patients achieved partial regression, while 1 patient experienced disease progression assessed 4 weeks after the third course. Three patients are still alive at the time of writing and have progression-free survival longer than 12 months. The overall survival time has been extended to over 12 months in 6 of the 9 patients. No constant changes of CD4+ T, B, and NK cells were recorded except for elevated CD8+ T cells after the first course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The combination of autologous iNKT cells and PD-1+CD8+ T cells was a safe therapeutic strategy against advanced pancreatic cancer. The patients exhibited a potentially promising prolonged survival time. Further study appears warranted to evaluate the efficacy of these combined cell infusions in pancreatic cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>This trial was included in the clinical trial which was registered in ClinicalTrials.gov (ID:NCT03093688) on March 15, 2017.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>There is an unmet need for novel, more effective, and tolerable therapies for pancreatic cancer. Here we present a phase I clinical trial employing iNKT cells combined with PD-1+CD8+ T cells in 9 patients with advanced pancreatic cancer and failing the first-line chemotherapy. The combined immunotherapy was shown to be feasible in the enrolled patients with limited side effects and optimistic clinical responses, which could bring opportunity of therapeutic advancement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0137","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T09:37:52Z","timestamp":1684834672000},"page":"991-1003","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5689-5128","authenticated-orcid":true,"given":"Jing","family":"Wang","sequence":"first","affiliation":[{"name":"1Shanghai Public Health Clinical Center, Fudan University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3456-6490","authenticated-orcid":true,"given":"Xiaobo","family":"Cheng","sequence":"additional","affiliation":[{"name":"2Clinical Research Center, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6546-5201","authenticated-orcid":true,"given":"Yanling","family":"Jin","sequence":"additional","affiliation":[{"name":"1Shanghai Public Health Clinical Center, Fudan University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6031-1404","authenticated-orcid":true,"given":"Bili","family":"Xia","sequence":"additional","affiliation":[{"name":"1Shanghai Public Health Clinical Center, Fudan University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0850-8403","authenticated-orcid":true,"given":"Ran","family":"Qin","sequence":"additional","affiliation":[{"name":"1Shanghai Public Health Clinical Center, Fudan University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9262-849X","authenticated-orcid":true,"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Shanghai Public Health Clinical Center, Fudan University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7552-6969","authenticated-orcid":true,"given":"Huiliang","family":"Hu","sequence":"additional","affiliation":[{"name":"1Shanghai Public Health Clinical Center, Fudan University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8951-6132","authenticated-orcid":true,"given":"Xiaoting","family":"Mao","sequence":"additional","affiliation":[{"name":"1Shanghai Public Health Clinical Center, Fudan University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6420-6897","authenticated-orcid":true,"given":"Liting","family":"Zhou","sequence":"additional","affiliation":[{"name":"1Shanghai Public Health Clinical Center, Fudan University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4638-7251","authenticated-orcid":true,"given":"Jia","family":"Yan","sequence":"additional","affiliation":[{"name":"1Shanghai Public Health Clinical Center, Fudan University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3193-1401","authenticated-orcid":true,"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"3Shanghai Public Health Clinical Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, P.R. China."},{"name":"4Clinical Center for Biotherapy, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, P.R. China."},{"name":"5Clinical Center for Biotherapy, Zhongshan Hospital, Fudan University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0896-9273","authenticated-orcid":true,"given":"Jianqing","family":"Xu","sequence":"additional","affiliation":[{"name":"3Shanghai Public Health Clinical Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, P.R. China."},{"name":"4Clinical Center for Biotherapy, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, P.R. China."},{"name":"5Clinical Center for Biotherapy, Zhongshan Hospital, Fudan University, Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"2023060714024455100_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2023060714024455100_bib2","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1200\/JCO.2018.78.9636","article-title":"Metastatic pancreatic cancer: ASCO clinical practice guideline update","volume":"36","author":"Sohal","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023060714024455100_bib3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/jnci\/djab122","article-title":"Association of the COVID-19 pandemic with patterns of statewide cancer services","volume":"114","author":"Yabroff","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"2023060714024455100_bib4","article-title":"Cancer stat facts: pancreatic cancer","author":"NCI"},{"key":"2023060714024455100_bib5","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/annonc\/mdt166","article-title":"Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials","volume":"24","author":"Rahma","year":"2013","journal-title":"Ann Oncol"},{"key":"2023060714024455100_bib6","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"2023060714024455100_bib7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"2023060714024455100_bib8","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"2023060714024455100_bib9","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1158\/1078-0432.CCR-10-0041","article-title":"Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients","volume":"16","author":"Besser","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2023060714024455100_bib10","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J Clin Oncol"},{"key":"2023060714024455100_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40425-016-0164-7","article-title":"Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors","volume":"4","author":"Hall","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2023060714024455100_bib12","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2023060714024455100_bib13","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-13-0371","article-title":"Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors","volume":"73","author":"Rusakiewicz","year":"2013","journal-title":"Cancer Res"},{"key":"2023060714024455100_bib14","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bjc.2013.32","article-title":"Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer","volume":"108","author":"Ino","year":"2013","journal-title":"Br J Cancer"},{"key":"2023060714024455100_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nm.4051","article-title":"Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients","volume":"22","author":"Gros","year":"2016","journal-title":"Nat Med"},{"key":"2023060714024455100_bib16","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/CJI.0b013e3181fad2b0","article-title":"Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells","volume":"33","author":"Inozume","year":"2010","journal-title":"J Immunother"},{"key":"2023060714024455100_bib17","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors","volume":"124","author":"Gros","year":"2014","journal-title":"J Clin Invest"},{"key":"2023060714024455100_bib18","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1158\/0008-5472.CAN-20-2300","article-title":"T Cells expanded from PD-1(+) peripheral blood lymphocytes share more clones with paired tumor-infiltrating lymphocytes","volume":"81","author":"Li","year":"2021","journal-title":"Cancer Res"},{"key":"2023060714024455100_bib19","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1158\/0008-5472.CAN-17-0236","article-title":"Expansion of tumor-infiltrating CD8(+) T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy","volume":"77","author":"Fernandez-Poma","year":"2017","journal-title":"Cancer Res"},{"key":"2023060714024455100_bib20","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00262-014-1575-2","article-title":"A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma","volume":"63","author":"Poschke","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"2023060714024455100_bib21","doi-asserted-by":"crossref","first-page":"16607","DOI":"10.1038\/s41598-017-16832-1","article-title":"Improved detection of cytokines produced by invariant NKT cells","volume":"7","author":"Sag","year":"2017","journal-title":"Sci Rep"},{"key":"2023060714024455100_bib22","doi-asserted-by":"crossref","first-page":"11287","DOI":"10.1073\/pnas.0801631105","article-title":"Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population","volume":"105","author":"Coquet","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023060714024455100_bib23","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.3390\/cancers13205174","article-title":"The current landscape of NKT cell immunotherapy and the hills ahead","volume":"13","author":"Nelson","year":"2021","journal-title":"Cancers"},{"key":"2023060714024455100_bib24","doi-asserted-by":"crossref","first-page":"e995562","DOI":"10.1080\/2162402X.2014.995562","article-title":"Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice","volume":"4","author":"Gebremeskel","year":"2015","journal-title":"Oncoimmunology"},{"key":"2023060714024455100_bib25","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1172\/JCI37869","article-title":"Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages","volume":"119","author":"Song","year":"2009","journal-title":"J Clin Invest"},{"key":"2023060714024455100_bib26","doi-asserted-by":"crossref","first-page":"648917","DOI":"10.3389\/fimmu.2021.648917","article-title":"Deciphering the prognostic implications of the components and signatures in the immune microenvironment of pancreatic ductal adenocarcinoma","volume":"12","author":"Tang","year":"2021","journal-title":"Front Immunol"},{"key":"2023060714024455100_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clim.2010.11.010","article-title":"Clinical experience with alpha-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B\/C infection","volume":"140","author":"Schneiders","year":"2011","journal-title":"Clin Immunol"},{"key":"2023060714024455100_bib28","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.4049\/jimmunol.167.7.4046","article-title":"Loss of IFN-gamma production by invariant NK T cells in advanced cancer","volume":"167","author":"Muhammad Ali Tahir","year":"2001","journal-title":"J Immunol"},{"key":"2023060714024455100_bib29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3389\/fimmu.2013.00409","article-title":"NKT cells as an ideal anti-tumor immunotherapeutic","volume":"4","author":"Fujii","year":"2013","journal-title":"Front Immunol"},{"key":"2023060714024455100_bib30","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3389\/fimmu.2019.01126","article-title":"\u03b1-GalCer and iNKT cell-based cancer immunotherapy: realizing the therapeutic potentials","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"2023060714024455100_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.clim.2010.11.014","article-title":"Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy","volume":"138","author":"Yamasaki","year":"2011","journal-title":"Clin Immunol"},{"key":"2023060714024455100_bib32","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.4049\/jimmunol.0800126","article-title":"A phase I-II study of alpha-galactosylceramide-pulsed IL-2\/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer","volume":"182","author":"Motohashi","year":"2009","journal-title":"J Immunol"},{"key":"2023060714024455100_bib33","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1349-7006.2009.01135.x","article-title":"Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma","volume":"100","author":"Kunii","year":"2009","journal-title":"Cancer Sci"},{"key":"2023060714024455100_bib34","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2217\/imt-2021-0247","article-title":"Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient","volume":"14","author":"Wang","year":"2022","journal-title":"Immunotherapy"},{"key":"2023060714024455100_bib35","doi-asserted-by":"crossref","first-page":"eabn6563","DOI":"10.1126\/sciimmunol.abn6563","article-title":"TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells","volume":"7","author":"Delfanti","year":"2022","journal-title":"Sci Immunol"},{"key":"2023060714024455100_bib36","doi-asserted-by":"crossref","first-page":"108992","DOI":"10.1016\/j.clim.2022.108992","article-title":"Feasibility of iNKT cell and PD-1+CD8+ T cell-based immunotherapy in patients with lung adenocarcinoma: preliminary results of a phase I\/II clinical trial","volume":"238","author":"Cheng","year":"2022","journal-title":"Clin Immunol"},{"key":"2023060714024455100_bib37","doi-asserted-by":"crossref","first-page":"1027619","DOI":"10.3389\/fbioe.2022.1027619","article-title":"Improving the ex vivo expansion of human tumor-reactive CD8 + T cells by targeting toll-like receptors","volume":"10","author":"Qiu","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"2023060714024455100_bib38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-1-0716-1775-5_11","article-title":"Expansion of human iNKT cells ex vivo","volume":"2388","author":"Wang","year":"2021","journal-title":"Methods Mol Biol"},{"key":"2023060714024455100_bib39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nprot.2007.515","article-title":"Methods for detection, isolation and culture of mouse and human invariant NKT cells","volume":"3","author":"Watarai","year":"2008","journal-title":"Nat Protoc"},{"key":"2023060714024455100_bib40","doi-asserted-by":"crossref","first-page":"652875","DOI":"10.1155\/2015\/652875","article-title":"Antitumor responses of invariant natural killer T cells","volume":"2015","author":"Altman","year":"2015","journal-title":"J Immunol Res"},{"key":"2023060714024455100_bib41","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"key":"2023060714024455100_bib42","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1158\/1078-0432.CCR-16-0600","article-title":"Adoptive transfer of invariant NKT cells as immunotherapy for advanced melanoma: a phase I clinical trial","volume":"23","author":"Exley","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2023060714024455100_bib43","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41577-018-0034-2","article-title":"Tissue-specific functions of invariant natural killer T cells","volume":"18","author":"Crosby","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2023060714024455100_bib44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/jso.24627","article-title":"CAR T-cell therapy for pancreatic cancer","volume":"116","author":"DeSelm","year":"2017","journal-title":"J Surg Oncol"},{"key":"2023060714024455100_bib45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"2023060714024455100_bib46","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clim.2010.11.010","article-title":"Clinical experience with alpha-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B\/C infection","volume":"140","author":"Schneiders","year":"2011","journal-title":"Clin Immunol"},{"key":"2023060714024455100_bib47","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10875-012-9697-9","article-title":"Accumulation of activated invariant natural killer T cells in the tumor microenvironment after alpha-galactosylceramide-pulsed antigen presenting cells","volume":"32","author":"Nagato","year":"2012","journal-title":"J Clin Immunol"},{"key":"2023060714024455100_bib48","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.4049\/jimmunol.167.7.4046","article-title":"Loss of IFN-gamma production by invariant NK T cells in advanced cancer","volume":"167","author":"Muhammad Ali Tahir","year":"2001","journal-title":"J Immunol"},{"key":"2023060714024455100_bib49","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1365-2141.2003.04465.x","article-title":"Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes","volume":"122","author":"Fujii","year":"2003","journal-title":"Br J Haematol"},{"key":"2023060714024455100_bib50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ijc.20998","article-title":"Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load","volume":"116","author":"Molling","year":"2005","journal-title":"Int J Cancer"},{"key":"2023060714024455100_bib51","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1084\/jem.20021650","article-title":"A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma","volume":"197","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"key":"2023060714024455100_bib52","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clim.2011.04.017","article-title":"Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects","volume":"140","author":"Exley","year":"2011","journal-title":"Clin Immunol"},{"key":"2023060714024455100_bib53","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/j.ymthe.2020.06.025","article-title":"Reactive myelopoiesis triggered by lymphodepleting chemotherapy limits the efficacy of adoptive T cell therapy","volume":"28","author":"Innamarato","year":"2020","journal-title":"Mol Ther"},{"key":"2023060714024455100_bib54","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"2023060714024455100_bib55","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00262-022-03287-1","article-title":"Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) therapy: a systematic review and meta-analysis","volume":"72","author":"Owen","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2023060714024455100_bib56","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1158\/2159-8290.CD-21-1248","article-title":"Single-cell sequencing reveals trajectory of tumor-infiltrating lymphocyte states in pancreatic cancer","volume":"12","author":"Schalck","year":"2022","journal-title":"Cancer Discov"},{"key":"2023060714024455100_bib57","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3390\/cancers15030724","article-title":"Therapeutic strategies to overcome fibrotic barriers to nanomedicine in the pancreatic tumor microenvironment","volume":"15","author":"Tanaka","year":"2023","journal-title":"Cancers"},{"key":"2023060714024455100_bib58","doi-asserted-by":"crossref","first-page":"120077","DOI":"10.1016\/j.biomaterials.2020.120077","article-title":"Heterotypic 3D pancreatic cancer model with tunable proportion of fibrotic elements","volume":"251","author":"Tanaka","year":"2020","journal-title":"Biomaterials"},{"key":"2023060714024455100_bib59","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.2217\/fon-2021-1549","article-title":"Immunotherapy for liposarcoma: emerging opportunities and challenges","volume":"18","author":"Song","year":"2022","journal-title":"Future Oncol"},{"key":"2023060714024455100_bib60","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/1759-7714.14529","article-title":"Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancer","volume":"13","author":"Miyawaki","year":"2022","journal-title":"Thorac Cancer"},{"key":"2023060714024455100_bib61","doi-asserted-by":"crossref","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/doi\/10.1158\/2767-9764.CRC-23-0137\/726715\/Safety-and-clinical-response-to-combined","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/6\/991\/3339207\/crc-23-0137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/6\/991\/3339207\/crc-23-0137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T10:04:39Z","timestamp":1686132279000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/6\/991\/727187\/Safety-and-Clinical-Response-to-Combined"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,7]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0137","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.23312563","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312551","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312542.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23098887","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23098875","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23098890","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23098866.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312545.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23098869.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312563.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312572","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312560","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312557.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312536","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312572.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312551.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312569.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312554.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312560.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312566.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312569","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312557","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312545","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23098869","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23098872.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23098872","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312530.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23098884","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312536.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312539.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6660294.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312530","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6660294","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23098890.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23098884.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23098875.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23098866","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312566","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312554","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312542","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312539","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23098887.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6660294.v1","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.23312539.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312536.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312551.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312545","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312557","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312554.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312569","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312557.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312569.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312530","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312542","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312554","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312566","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312530.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312542.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312545.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312563","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312551","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312539","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312563.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312560.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312572.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312566.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312560","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312572","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23312536","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]}}}